AU2019247383B2 - Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells - Google Patents

Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells

Info

Publication number
AU2019247383B2
AU2019247383B2 AU2019247383A AU2019247383A AU2019247383B2 AU 2019247383 B2 AU2019247383 B2 AU 2019247383B2 AU 2019247383 A AU2019247383 A AU 2019247383A AU 2019247383 A AU2019247383 A AU 2019247383A AU 2019247383 B2 AU2019247383 B2 AU 2019247383B2
Authority
AU
Australia
Prior art keywords
hct
mscs
infusion
study
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019247383A
Other languages
English (en)
Other versions
AU2019247383A1 (en
Inventor
Charles Michael COTTEN
Joanne Kurtzberg
Allen Song
Jessica Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2019247383A1 publication Critical patent/AU2019247383A1/en
Application granted granted Critical
Publication of AU2019247383B2 publication Critical patent/AU2019247383B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2019247383A 2018-04-04 2019-04-04 Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells Active AU2019247383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652818P 2018-04-04 2018-04-04
US62/652,818 2018-04-04
PCT/US2019/025796 WO2019195554A1 (en) 2018-04-04 2019-04-04 Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells

Publications (2)

Publication Number Publication Date
AU2019247383A1 AU2019247383A1 (en) 2020-10-29
AU2019247383B2 true AU2019247383B2 (en) 2025-11-27

Family

ID=68101217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019247383A Active AU2019247383B2 (en) 2018-04-04 2019-04-04 Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells

Country Status (11)

Country Link
US (1) US20210361716A1 (https=)
EP (1) EP3773624A4 (https=)
JP (1) JP2021520353A (https=)
KR (1) KR20210021946A (https=)
CN (1) CN112236152A (https=)
AU (1) AU2019247383B2 (https=)
BR (1) BR112020020288A2 (https=)
CA (1) CA3096037A1 (https=)
IL (1) IL277732A (https=)
SG (1) SG11202009800SA (https=)
WO (1) WO2019195554A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024075676A1 (ja) * 2022-10-03 2024-04-11 キッズウェル・バイオ株式会社 脳性まひの予防又は治療剤
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1803193A (zh) * 2005-01-13 2006-07-19 中山大学 骨髓来源的间质干细胞用于制备治疗缺氧缺血性脑性瘫痪的制剂的用途
US20070128722A1 (en) * 2005-12-05 2007-06-07 Industrial Technology Research Institute Human mesenchymal stem cells and culturing methods thereof
US20170042944A1 (en) * 2014-04-21 2017-02-16 Anthrogenesis Corporation Treatment of conditions and complications in infants
WO2016019332A1 (en) * 2014-07-29 2016-02-04 Ingeneron, Inc. Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof
WO2017144552A1 (en) * 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
JP7126703B2 (ja) * 2016-05-24 2022-08-29 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
KR101973284B1 (ko) * 2017-01-16 2019-04-29 사회복지법인 삼성생명공익재단 신생아 ｈｉｅ 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIMING WANG ET AL: "Therapeutic Potential of Umbilical Cord Mesenchymal Stromal Cells Transplantation for Cerebral Palsy: A Case Report", CASE REPORTS IN TRANSPLANTATION, vol. 2013, 1 January 2013 *

Also Published As

Publication number Publication date
EP3773624A4 (en) 2022-01-12
WO2019195554A1 (en) 2019-10-10
AU2019247383A1 (en) 2020-10-29
KR20210021946A (ko) 2021-03-02
EP3773624A1 (en) 2021-02-17
BR112020020288A2 (pt) 2021-01-12
SG11202009800SA (en) 2020-11-27
IL277732A (en) 2020-11-30
US20210361716A1 (en) 2021-11-25
CA3096037A1 (en) 2019-10-10
CN112236152A (zh) 2021-01-15
JP2021520353A (ja) 2021-08-19

Similar Documents

Publication Publication Date Title
Baak et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study
Bruschettini et al. Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants
Nnodu Interventions for the prevention and control of sickle cell disease at primary health care centres in Gwagwalada Area Council of the Federal Capital Territory, Nigeria
Lanci et al. Dystocia in the standardbred mare: a retrospective study from 2004 to 2020
AU2019247383B2 (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Sato et al. Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial)
US11813294B2 (en) Methods for the treatment of autism spectrum disorders
EP3773486B1 (en) Umbilical cord tissue-derived mesenchymal stromal cells for use in the treatment of autism spectrum disorders
Phillips et al. Perinatal and neonatal implications of sickle cell disease
US20200016213A1 (en) Methods of Treating Cerebral Palsy Using High Dose Allogeneic Umbilical Cord Blood
HK40044465A (en) Methods of treating cerebral palsy and hypoxic-ischemic encephalopathy using human umbilical cord tissue-derived mesenchymal stromal cells
Saitoh et al. Safety and feasibility of allogeneic sibling cord blood infusion in Japanese children with cerebral palsy: A single-center pilot study
US20250312383A1 (en) Human umbilical cord blood for use in alleviating fatigue
Pouraboli et al. The effect of early skin to skin contact on maternal attachment behaviors in neonates after cesarean section
Mazalon et al. The significance of medical history and its impact on the early diagnosis of inborn errors of immunity
Waddell et al. Anaesthesia for patients with sickle cell and other haemoglobinopathies
Bales The Long-Term Effects of Pitocin Administered during Labor on a Childs Social Development
Holder Distance Traveled for Intrapartum Care and Perinatal Outcomes in Eastern North Carolina
HK40045701A (en) Methods of treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Snyder Ethical issues in hematopoietic cell transplantation
Ali et al. 1 Paediatric Transport Safety Collaborative (PTSIC): Critical Events with Family Presence During Paediatric Critical Care Transport
Parvez et al. 3 In-Hospital Child Mortality after Consolidation of Two Pediatric Intensive Care Units
Chambers et al. International Journal of Population Data Science
Zaidi et al. Frequency of Low Birth Weight Babies and Scio-Economic Status among the Mothers of Karachi
Egbi NIGER DELTA MEDICAL JOURNAL

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)